{
  "doc_id": "baggrund-for-medicinraadets-anbefaling-vedr-lenvatinib-som-mulig-standardbehandling-til-hepatocellulaert-karcinom-vers-10-med-bilag_adlegacy",
  "created_date": "unknown_year",
  "country": "DK",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "r. r.: d d y",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Medical Medical Council",
      "text": "regions. regions.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "On the recommendation",
      "text": "Medical Medical Council'medicine. medicine.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Document information",
      "text": "Date of approval: into into force: 0 0 © Ø Ø Language: Danish Format: ansål ansål ......ggrund................ ring ring .................... rsionslog rsionslog ... . . . ng severity/value value . .. .",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "prescription. prescription.",
      "text": "__MTTERM4_. __MTTERM4_. Administration/mg mg (weight weight < 60 kg) mg mg ( weight weight ≥ 60 kg), carcinoma carcinoma (HCC) past. past.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "Medical Medical Council",
      "text": "carcinoma carcinoma (HCC) as as follows: to to __medterm2_? of of 8",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "3 Purpose",
      "text": "Council. Council.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "4 Background",
      "text": "Medical Medical Council'medical medical council'days. days.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Medical Medical Board",
      "text": "B B (7), __MIDTERM1__, __MIDTERM1__, provides: • value value (evidence evidence quality) carcinoma. carcinoma.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "6 Consultation",
      "text": "2019. 2019.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "decision-making decision-making bases",
      "text": "price price (SAIP) about about severity/midomko midomko __MEDERTM4__-, the the board'Væreftefsen. Væreftefsen.",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Medical Medical Council",
      "text": "Ø Ø medicraadet@medicinsraadet.dk",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Secretariat working group",
      "text": "Gedske Thomsen (Christensen Christensen (Nielsen Nielsen (Nielsen Nielsen (gskoor gskoor Dej) cancer cancer lig) onsule or) Patienter Patienter ent) 8 8 o",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "11 Annex",
      "text": "List of annexes: • Amgr • Amgr • Hørin • Vurde • Application • praises praises • Amgros Amgros I/T T +F F +45 88713008 Medicin@amgros.dk",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "lenvatinib lenvatinib (Lenvima) for for patients",
      "text": "stage stage (BCLC stage C) drug drug (based on SAIP) Medical Medical Board'Decision Decision 10-Eisai Eisai (applicant) Drug __MEDTERM0_ (Lenvima) with with state-of-the-art (BclC stage c) Child Child -PughA or B",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Amgro's assessment",
      "text": "• lenvatinib lenvatinib (Lenvima) stage stage (BCLC stage C) __MIDTERM0__ __MIDTERM0__ (Lendima) __medterm2__ __medterm2__ [Nexavar] lenvatinib_ lenvatinib_ (Lenvima), __midterm2__ __midterm2__ (Nexavar).",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Other considerations",
      "text": "__MEDTERM0_ __MEDTERM0_ (Lenvima) __medterm0_ __medterm0_ [Lenvida) the the patient'of of Amgrose'__midterm0__ __midterm0__ (Lendima) __mediterm3_ __mediterm3_ (Nexavar). assessment assessment (based on SAip) Sorafenib_ Sorafenib_ (Nexavar) Table Table 2: Result of Amgro'__MEDTERM0_ __MEDTERM0_ (Lenvima) __MIDTERM13__ __MIDTERM13__ (Lendima) __medterm4_ (Nexavar) Incremental Omkos (DKK) XX XX € lenva lenva (LENVIMA) with with __midTERM3___[NexaDVAR] DKK. DKK.",
      "start_page": 11,
      "end_page": 13
    },
    {
      "heading": "Background",
      "text": "Lenvatinib (Lenvima) carcinoma carcinoma (HCC) Eisai. Eisai.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Analysis",
      "text": "lenvatinib lenvatinib (Lenvima) sorafenib sorafenib (Nexavar) stage stage (BCLC sta- die C) B. B.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "budgetary budgetary consequences",
      "text": "__MEDTERM0_ __MEDTERM0_ (Lenvima) scenario scenario Amgro'using using ~MEDTERMO_ (Lendima) __medterm2__ __medterm2__ (Nexavar) recommendation recommendation __MEDTERM0_[Lenvima] year year .",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Conclusion",
      "text": "lenvatinib lenvatinib (Lenvima) comparator. comparator.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "2 __MEDTERM0_ (LENVIMA)",
      "text": "NIB NIB (mm mm MA) m m Ma) S S S",
      "start_page": 15,
      "end_page": 16
    },
    {
      "heading": "LOG",
      "text": "Application Pharmaceutical company: Eisa Trade name: Lenv Generic name: Lenn Indication: Beh ATC code: L01X",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Process",
      "text": "at at Amgros: Final report completed: Working Working Group:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Prices",
      "text": "is is further",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "5 LENVATINIB (LENVIMA)",
      "text": "XE29 XE29 increase: prices prices (AIP).",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "1 BACKGROUND",
      "text": "Lenvatinib (Lenvima) carcinoma carcinoma (HCC) Eisai Eisai (an an applicant) __MIDTERM1_ __MIDTERM1_ (Lenvima), lenvatinib lenvatinib (Lendima) is is Amgroso'analyses analyses (the the analysis).",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "1.1 Problem",
      "text": "carcinoma carcinoma (HCC) lenvatinib lenvatinib (Lenvima) indication. indication.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Patient Patient population",
      "text": "year year (\"1). is is 37% and and 40% only only 9% and and 11% for women[1]. liver liver function(1). X",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "__MEDTERM0_ __MEDTERM0_ (Lenvima)",
      "text": "Cancer Cancer (BCLC) stage stage (BclC C), therapy therapy (1st-line) indication Lenvatinib (Lenvima) and and B(1). __MEDTERMM0_ (Lenovima) growth growth factor*.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "6 __MEDTERM0_ (LENVIMA)",
      "text": "Dosage Lenvatinib (Lenvima) as as tablets: • weight weight < 60 kg • weight weight ≥ 60 kg",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "1 1 Comparator",
      "text": "• sorafenib sorafenib (Nexavar) __MIDTERM1_ __MIDTERM1_ (Nexavar) mg mg (twice twice daily) Table 1: Sorafenib Sorafenib (NIxavar) and and B",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Medical Medical Council",
      "text": "• lenvatinib lenvatinib (Lenvima) __MIDTERM1__ __MIDTERM1__ (Nexavar)?",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "ECONOMIC ECONOMIC ANALYSIS",
      "text": "__MEDTERM0_ __MEDTERM0_ (Lenvima) __MIDTERM1__ __MIDTERM1__ (Nexavar) presented. presented.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Model Model description",
      "text": "survival survival (PFS), disease disease (PD) and Survival (_MEDTERM3__). the the patient'al al (2018)(2). extrapolated extrapolated __MEDTERM2_% __medTERM0_ __medTERM0_ (Lenvima) __medterm1_ __medterm1_ (years. years.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Analysis Analysis perspective",
      "text": "of of 4%. Amgros ■ Assessment The analysis'with with Amgro'25 25 years; the the analysis' frame. frame.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "8 __MEDTERM0_ (LENVIMA)",
      "text": "the the analysis",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "medicinal medicinal products",
      "text": "days. days. Applicant'lenvatinib_ lenvatinib_ (Len- 4 mg) __MEDTERM2_ __MEDTERM2_ (Lend-XX Amgros vima) pcs. pcs. (Nexavar). __medterm2___ __medterm2___ (Lens-vima) and __midTERM3_ (NexaPD). for for 50% that that 0% made made 25% that that 46% 9__ 9__ -stage and 48% respectively. respectively.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "9 __MEDTERM0_ (LENVIMA)",
      "text": "Shop-Shop-Rail-Low-Light-Back-Lough-Look-Lash-Lill-Law-Lum-Lim-Lam-Lah-Luh-Lut-Lab-Lay-Lump-Long-Limi-Lat-Lav-Lig-Lad-Lold-Lus-Lom-Lu-Lun-Lud-Lur-Lall-Land-Len-Lem-Lid-Lin-Lama-Laj-Luk-Lou-Lit-Lau-Lap-Lup-Lub-Lug-Lax-Limp-Lust-Lake-Lip-Luff-Life-Learn-Lag-Lik-Lix-Lib-Lil-Li-Luc-Lac-Lak-Lich-Lux-Leu-Lind-Lick-Lock-Link-Lol-Lar-Lyl-List-where where ≥ 5% in in ≤ 5% and and 4) occurred in ≤ __MEDTERM2_ __MEDTERM2_ (Lenvima) and sorafenib (Nexavar). Table 6: % and and 4% of patients respectively; Palmar-plantar Palmar-plantar eryt- 2. 2.56",
      "start_page": 22,
      "end_page": 24
    },
    {
      "heading": "12 __MEDTERM0_ (LENVIMA)",
      "text": "sorafenib_ sorafenib_ (Nexavar) al. al. (2018), arm. arm.(2) Ambulants Ambulants &amp; ___medterm0_ ___medterm0_ (nexavar), patient patient ≥Lenvatinib_ Lenvatinib_ _=model. model.",
      "start_page": 24,
      "end_page": 25
    },
    {
      "heading": "Sensitivity Sensitivity analyses",
      "text": "since since Amgro'varies varies -+20%. in in Denmark; relevant. relevant.",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "the the applicant's main analysis",
      "text": "• __MEDTERM0_ __MEDTERM0_ (L • per per • is is included",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "the the applicant's main analysis",
      "text": "Table Table 7: the the applicant'__MEDTERM0_ __MEDTERM0_ (Lenvatinib Lenvatinib (Lenvima) outside outside at- average average cost- per per patient",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "the the applicant",
      "text": "the the applicant'for for results",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "14 __MEDTERM0_ (LENVIMA)",
      "text": "Lenvima) and sorafenib (medians medians ma) SorafenibInkr SorafenibInkr (Nexavar) a. a. avar) r. ib (Nexavar), omko omko (DKK) DKK DKK - illustrates illustrates applicant'Table Table 8: ____ ____ (Lenvima) __ (nexavar) 2.",
      "start_page": 26,
      "end_page": 27
    },
    {
      "heading": "in in Amgro's main analysis",
      "text": "the the applicant'following following adjustments: • tinib tinib (Lenvima) and sorafenib (Nexavar) • Ambros includes waste",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "of of Amgro's main analysis",
      "text": "lenvatinib lenvatinib (Lenvima) Table Table 9: Result of Amgro'__medterm0__ __medterm0__ (Lendima) element element __medterm2___[Lenvima] Sorafenib [Nexavar) outside outside - average average cost- XX XX DKK",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "15 __MEDTERM0_ (LENVIMA)",
      "text": "cost cost (DKK) costs costs (DKkK) __medterm1__ __medterm1__ (Lenvima) __MEDTERM0_ __MEDTERM0_ (Nexavar) 000. 000.",
      "start_page": 27,
      "end_page": 28
    },
    {
      "heading": "Sensitivity Sensitivity Analysis",
      "text": "medical medical council'patients patients (60 60 kg), adjusts adjusts mg/patient patient ≤ and and ≥ Table Table 10: Result of Amgro'patient patient < Lenvatinib_ Lenvatinib_ (Lenvima) costs costs (DKK) XX XX (basecase) ≤ XXXxxX XXXxxX ≥ XX2XX XX2XX DKK",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "4 BUDGET CONSEQUENCES",
      "text": "two two scenarios: __MEDTERM0_ __MEDTERM0_ (Lenvima) __medterm0__ __medterm0__ (Lenvima). year. year.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "impact impact assessment",
      "text": "of of Amgro'Table Table 11: Lenvatinib Lenvatinib (Lenvima) __MEDTERM1_ __MEDTERM1_ (Lendima) annum. annum.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Scenario Scenario analysis",
      "text": "lenvatinib lenvatinib (Len-vima) is recommended.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "17 __MEDTERM0_ (LENVIMA)",
      "text": "Table 12: Number Number (8 paties) Number Number (20 pat enter) on on XXXX",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "18 __MEDTERM0_ (LENVIMA)",
      "text": "as as a- XXX ti- inib inib (0 0 ma) recommended, recommended, bid-vima) budget budget con-",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "5 DISCUSSION",
      "text": "lenvatinib lenvatinib (Lenvima) _MEDTERM1__ _MEDTERM1__ (Nexavar). __MIDTERM0__ __MIDTERM0__ (Lendima). __medterm0_ __medterm0_ (Lendima) consequences. consequences.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "6 REFERENCES",
      "text": "carcinoma. carcinoma. 2018;Document number: AMGROS AMGROS I/Ø Ø TLF: Medical Medical Council'carcinoma carcinoma 19/03/evidence. evidence.",
      "start_page": 32,
      "end_page": 34
    },
    {
      "heading": "studies studies (of of report)",
      "text": "estimates. estimates. • levels levels ≥ 200 ng/_46. _46.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "assessment assessment (of of report)",
      "text": "when when __medTERM39__- __MIDM3______when __MIDM3______when , of of 95% CI <1 (95% CI: 9955, 9955, p=0.00342). EMA EMA . . ..0342)). market. market.",
      "start_page": 34,
      "end_page": 36
    },
    {
      "heading": "added added value:",
      "text": "following following categories: added added value: added added value; value value - standard standard treatment/value value (negative value) default default treatment/Other treatments.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Medical Medical Council:",
      "text": "regions. regions. © th. th., Ø Ø Language: Danish Format: 2019. 2019.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "of of 21",
      "text": "Forko BCAMC: CHMP: CI: EMA: EPAR: EORTC EORT ESMO: GRADE HCC: HR: ITT: MeSH: __MEDTERM0_: PICO: RFA: RR: SAE: SD: LQ LQ E: Q-HCC Q-HCC C18: Treatmentnaire Treatmentnaire -evidence evidence (Grade of Reclair)",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "Contents",
      "text": "2 Background .............................................................3 Method ...............................................literature literature ............................................processing processing ..................................value value ...............questions questions ..................studies studies ..................assessment assessment ................. evidence evidence .................Conclusion Conclusion ...................considerations considerations ..................8 The Council'References References ..................consultation consultation ..12 Annex 1: profiles profiles .....................................Bias Bias ...................composition composition ......",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "1 Purpose",
      "text": "Medical Medical Council'group group (comparators).",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "2 Background",
      "text": "almost almost 3⁄cases cases [2]. 37 37 % 40 40 % 9 9 % 11 11 % for females [2]. Cancer Cancer (BCLC) stage stage (BCLC stage C), symptoms symptoms and/liver liver [3]. year year [4]. __MEDTERMM0_ __MEDTERMM0_ [5]. health health and/ Child Child -symptomatically symptomatically [3].",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "of of 21",
      "text": "mg mg (weight weight < 60 kg) mg mg ( weight weight ≥ 60 kg), kg. kg. __medterm0_] occur. occur. }",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "3 Method",
      "text": "2018. 2018.",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "4 Literature search",
      "text": "The Applicant'Medical Medical Council'trial trial is: • REFLECT: Kudo M., hepatocellular hepatocellular carcinoma: Non-inference Non-inference trial; studies. studies.",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "of of 21",
      "text": "objective. objective.",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "5 Data processing",
      "text": "as as 95% confidence intervals.",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "Conclusion clinical issues",
      "text": "to to __MIDTERM1__? added-value added-value (evidence evidence quality).",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "of of studies",
      "text": "the the study: %$$$ $$$#$$%$$*$$=$$_$$£$$~$${$$/%%$##$#%$%#$%%###[$$•$$^$$ ($$) $$%=##%%%=$#!## ### _______$$ £$#\\$$W > %##+## arm arm (you you (lenvatinib) Sorafenib Sorafenib (n = 476) A: 99 % B: 1% Yes: 19 % No: 81 % Yes: 62 % No.: 38 % Yeah: 76% No: 24 % Hepatitis B: 48 % Hepatitis C: 26 % Alcohol: 4 % Other: 7 % Unknown: 14 % B (intermediate): 19 % C (advanced): 81 %",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "of of 21",
      "text": "between between lenvatinib- size size (on on prognosis).",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "and and assessment",
      "text": "OS OS (critical) added added value: Median Median survival: Median Median viability: months months survival: 8 % months months survivability: 5 % survival survival rate: 4 % months months survivor: 3,7 % limit limit < threshold threshold < level level < limit limit > 1,00 HR: 0,92 [0,79;1,06] threshold threshold > 1.00 Evidence'assessment. assessment.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "of of 21",
      "text": "difference difference HR: 0.92 [0.79;1,06] 1. 1.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "Overall survival assessment",
      "text": "> MEDTERM0_- and sorafenibarm (33 % and 39 % respectively). the the patient'events. events.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "of of 21",
      "text": "5 5 % events events (RR) = 0.23 [0.79; 1.90] reactions. reactions.",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "of of 21",
      "text": "of of events/18 18 events/limit limit < threshold threshold < Limit Limit < limit limit > Rate Rate ratio: 0.89 [0.78;1.01] limit limit ≥ months months (_lenvatinibarm) months months (__MEDERTM1_arm). 59 59 events/kidneys kidneys (proteinuria) 11 11 %. grade grade ≥ in in 6% 2 2 % in ~___MEDTERM0_treatment ___MEDTERM0_treatment (16%) __methTERM1__treatment __methTERM1__treatment (2%).",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "of of 21",
      "text": "the the sorafenibUSE_USe_EXCEEDING) (52 % vs 27% respectively). relief relief (shoe inserts). patients patients (46 % vs 39 %).",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "adverse adverse reactions",
      "text": "profiles profiles (type and frequency), survival survival (important) objective objective •progress-free survivability· survival survival data; line. line.",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "value value assessment: Progression-free survival",
      "text": "66 66 [0.57;0.77]. interval interval < ratio ratio (living. living.",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "of of evidence",
      "text": "low. low.",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "4 4 Conclusion",
      "text": "B B (7) __MIDTERM1__ __MIDTERM1__ (of of evidence).between between __midd_ml_s_g_v_r_q_m_gf_g=v_g",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "7 Other considerations",
      "text": "options. options.",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "of of 21",
      "text": "efficiency efficiency (evidence evidence quality) B B (7) provides: with with dipping",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "10 References",
      "text": "Lancet. Lancet. 2018;391(10127):database database [internet]. [September September 2017]. Available from: ianc. ianc.fr/NORDCANS/DK/3. 3. (DDGCG) cancer cancer (HepatoCellular Carcinom, HCC). [interett]. 2012. Available as: cancer cancer (2015) SST [interent]. 2015 [cite 2017] available from: Medical Medical Council'carcinom carcinom [interetint]. from from the: file:///C:/Users/THI/O Regions/Sager/_MEDTERMEM1_/Litteratur_REVICE_T2",
      "start_page": 54,
      "end_page": 55
    },
    {
      "heading": "Medical Medical Council",
      "text": "Ø Ø medicraadet@medicinsraadet.dk",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Secretariat working group",
      "text": "• B B &amp; B • B B &gt; • B B = B = H H = risk (B = B B = B B + A A = B B = liability to B= BT BT = risk on B+ AT AT = B B = AB AB = BA BA = B B = b = Christensen Christensen (Nielsen Nielsen (Nielsen Nielsen (F F = health. health. n: Annex Annex 1: GRAD Cochrania'that that non- the the patient'The The investigator'obscured. obscured.",
      "start_page": 55,
      "end_page": 56
    },
    {
      "heading": "of of 21",
      "text": "survival survival (survival survival rate) Adverse Adverse reactions: Undesirable Undesirable effects: Undesirable Undesirable effect: Imprecision Imprecision __$considerations considerations (95 % CI) (95% CI) us",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "of of 21",
      "text": "biases biases (95 % CI) (95% CI) none none -/478 -/66 66 Median: months months • serially serially (87 87 [0.754; 1.13]",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "Explanations",
      "text": "the the patient's and investigator'affect affect patients' and investigators' The The patient' study study (al. al. 2018), data data aren'protocol. protocol.",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "of of 21",
      "text": "LE LE Carcinoma",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "Content",
      "text": "...... .... ... . .................... .... . ... . . . ... ....",
      "start_page": 59,
      "end_page": 61
    },
    {
      "heading": "kinase kinase inhibitors",
      "text": "market. market.",
      "start_page": 61,
      "end_page": 62
    },
    {
      "heading": "3 Summary",
      "text": "HCC HCC patients: impacting impacting patients; kinase kinase (RTK) receptors receptors (and and VEGR3) FGF receptors (other other RTFFR4) proliferation proliferation (growth growth factor). analysis analysis • More patient's had post-prospan-__MEDTHERM0______ __MEDTHERM0______ ... the the ._MEDTERM_arm (51% the the -_MEDM0",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "4 Literature search",
      "text": "107 107 (3) (c) Treaty. Treaty. Database: period period covered: results results for",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "Relevant Relevant studies",
      "text": "assessment assessment (Table 4.1). 4. 4.1: Reference Reference (journal, journal, year) study study (completion completion date) date date carcinoma: (M. M., G.000-304)",
      "start_page": 65,
      "end_page": 65
    },
    {
      "heading": "included included studies",
      "text": "phase phase 1/2 proof-study study (202, NCT00946153) study study (REFLECT REFLECT study) __MEDTERMM2__ __MEDTERMM2__ [2]. assessment assessment [4]. δ δ =1) was was < __MediterraneanM2_arm. __MediterraneanM2_arm.",
      "start_page": 65,
      "end_page": 67
    },
    {
      "heading": "questioning questioning 1",
      "text": "with with __MIDTERM1_?",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "relevant relevant studies",
      "text": "C C (stacking stacking system) disease. disease.",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "per per study",
      "text": "2018 2018 [1] research research [1].",
      "start_page": 68,
      "end_page": 69
    },
    {
      "heading": "Median survival",
      "text": "73. 73.4% 73. 73.5% for for .a a 95% __MEDAM8__ __MEDAM8__ it'for for £themedM1__ themedM1__ . . . __ENTTMM0 __ENTTMM0 ... . .",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "55. 55.0% for",
      "text": "Ireland. Ireland.",
      "start_page": 69,
      "end_page": 70
    },
    {
      "heading": "by by subgroup",
      "text": "and and BW; HR (2 2 [1]. (HATH STRIFIC) generally generally (see above), (a) Hier, (a), (h) (h=0.86), of of 95% CI was <1 (95% CI: 0. 0.995). • HCC HCC (C, C, alcohol) 0. 0.855; with 95% CI of (1. 1.013).",
      "start_page": 70,
      "end_page": 72
    },
    {
      "heading": "Overall Overall Survival",
      "text": "(N=478) (N=319) (N =476) Total Total (N=157) ( N=321) (N:478) TABLE 5.4: REGION REGION - FAS [2] Ratio Ratio (95% CI)* With With adjustment† 92 92 (1. 1.06) 0.87 (1. 1.01) 86 86 (1. 1.02) 0.83 (1. 1.00) 08 08 (1. 1.42) 0.93 (1. 1.23)",
      "start_page": 72,
      "end_page": 74
    },
    {
      "heading": "survival survival analysis",
      "text": "virus virus (HCV) __MEDTERM0_arm __MEDTERM0_arm (26% vs 19%, specifically), arm arm (26% vs 19%, respectively), Arm Arm (26% VS 19%, considerably), __ARMEM1_. __ARMEM1_.",
      "start_page": 74,
      "end_page": 75
    },
    {
      "heading": "Survival analysis",
      "text": "73. 73.4% 73. 73.5% __medterm1_____medTERM3__was __medterm1_____medTERM3__was 6% end end of",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "for for the",
      "text": "Excellence Excellence (NICE) __MEDTHERM0__ __MEDTHERM0__ (ID1089) [9].. characteristics. characteristics.",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "adverse adverse events",
      "text": "majority majority (> 98%) subjects subjects (75%) in the ~subjects subjects (66.5%) inthe __medterm1__arm (Table 5.5). TABLE 5.5: TEAES TEAES - SET SET [1.2] Lenvatinib_____MEDTERM5_ Lenvatinib_____MEDTERM5_ (N=476) (N=475) n (%) n (%) 470 470 (98.7) 472 (99.4) 447 447 (93.9) 452 (95.2) TEAE TEAE ≥ 357 357 (75.0) 316 (66.5) 270. 270.56",
      "start_page": 75,
      "end_page": 76
    },
    {
      "heading": "adverse adverse events",
      "text": "in in __MEDTERM1_arm; the the -the the ~12. 12.2% 18 18 months; 10. 10.7% agents agents [2]. TABLE 5.6: EXPOSURE EXPOSURE (EPISODES/SY) - SET SET [2] LenvatinibSorafenib LenvatinibSorafenib (N=476) (N=475) Total duration= n n (AE rate) Total measurement= n n [AE rate] 124 124 (18.89) 4,718 (19.73) Related TEAE ≥ 517 517 (1.59) 430 (1.80) 409 409 (2.98) Any TEAE≥023 023 (3.16) 795 (3.03) Related TEAE ≥517 517 (1.59) 430 (1.80)",
      "start_page": 76,
      "end_page": 78
    },
    {
      "heading": "adverse adverse events",
      "text": "190 190 (400%) 176 176 (37%) 42 42 (9%) 153 153 (32%) 181 181 (38%), 34 34 (7%) subjects [1]. the the EMA",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "Median progression-free survival",
      "text": "respectively respectively (HR = 0.66; 95% 0. 0.77; P<0.001).",
      "start_page": 78,
      "end_page": 79
    },
    {
      "heading": "by by subgroup",
      "text": "Median __MEDTERM12_ORXA'with with _MEDTERM1___; the HR (_MEDERTM0_:_MEDERM1_] was <__MediterraneanM0 __MediterraneanM0 -4 4 [1,2]. FIGURE 5.4: SUBGUPS SUBGUPS - FAS [1] hazard hazard ratio; control control limit; QLQ-C30, quality-of-life requestnaire C30; 5. 5.5: DOMAINS DOMAINS [1]",
      "start_page": 79,
      "end_page": 81
    },
    {
      "heading": "Comparative Comparative analyses",
      "text": "the the following: • __medTERM1___ __medTERM1___ .",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "6 References",
      "text": "Commission Regulation (EC) No 470/Regulation Regulation (EEC) No 2658/Tariff Tariff (p. p. 1). Research Research (CDER), Center for Biology",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "Literature search",
      "text": "MEDLINE MEDLINE (via PubMed) and CENTRAL (via Cochrane Library) indexed indexed (Headings, Headings, MeSH) indication. indication.",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "__MEDTERM0_AND hepatocellular carcinoma",
      "text": "7. 7.1: criteria criteria Population: OR OR Comparator: Lenvatinib Outcomes: Overall survival (_MEDTERM2__) Events Events (AE) survival survival (__MEDERM3_)",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "__MEDTERM0_AND hepatocellular carcinoma",
      "text": "(\"_Bivil_Supplementary Concept] OR \"__MEDTERM0_\"[All Fields]) AND (\"carcinoma, hepatocellular\"[MeSH Terms] OR (\"carcinoma'[Allields] AND \"hepatocellular'[All Fields ]) OR \"Y, Y, Misha",
      "start_page": 83,
      "end_page": 90
    },
    {
      "heading": "__MEDTERM0_AND hepatocellular carcinoma",
      "text": "Lenvatinib Lenvatinib (E7080) NCT01761266, NCT01761266, Https://clinicaltrials.gov/show/ct01761276, 2013",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "CLINICALTRIALS. CLINICALTRIALS.GOV",
      "text": "hematology hematology & oncology, 2015, 13(4), 232‐234",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "Hepatocellular Hepatocellular carcinoma: diseases. diseases. Conference: 2018, 2018, 27(Supplement 1), 24‐25",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "J J -virus virus (HBV). Hepatology. Conference: 2017, 2017, 66(Supplement 1), 740A‐741A",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "hepatocellular hepatocellular carcinoma: Organic Organic Carcinoma: 8. 8.",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "health. health. Conference: 2017, 2017, 20(9), A411‐to to CENTRAL: 2018 2018 • 1, 1, Embase",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "life life (HRQOL) carcinoma carcinoma (HCC) __MEDTERM0_ __MEDTERM0_ (LEN) or __medterm1_ (SOR). Hepatology. Conference: 2017, 2017, 66(Supplement 1), to to CENTRAL: 30 November 2017",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "Life Life (HRQOL) carcinoma carcinoma (HCC) __MEDTERM0_ __MEDTERM0_ (LEN) or __MIDTERM1_ (SOR). oncology. oncology. Conference: 2017, 2017, 28(Supplement 5), v210",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "life life (HRQOL) carcinoma carcinoma (HCC) __MEDTERM0_ __MEDTERM0_ (LEN) or __medterm1__ (SOR). health. health. Conference: 2017, 2017, 20(9), A454‐A455",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "__MEDTERM0_ __MEDTERM0_ (LEN) vs __MIDTERM1_ (SOR) patients patients (pts) carcinoma carcinoma (uHCC).",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "__MEDTERM0_ __MEDTERM0_ (LEN) vs __MIDTERM1_ (SOR) patients patients (PTS)carcinoma carcinoma (uHCC). oncology. oncology. Conference: 2017, 2017, 13(Supplement 4), 116 .",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "biomarkers biomarkers (BM) in patients (pts) __MEDTERM0_ __MEDTERM0_ (LEN) vs __MEDTERM1_ (SOR) carcinoma carcinoma (uHCC).",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "hepatocellular hepatocellular carcinoma: 2016, 2016, 17(14), 1923‐1936",
      "start_page": 98,
      "end_page": 99
    },
    {
      "heading": "hepatocellular hepatocellular carcinoma",
      "text": "0 0 results",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "Exclusion",
      "text": "exclusion exclusion criteria: - trial trial - trial trial - selected selected - goals. goals.",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "PubMed",
      "text": "1: T. T., Michitaka Michitaka K; HCC HCC (RELPEC) Group Group (in in Japan).",
      "start_page": 99,
      "end_page": 105
    },
    {
      "heading": "oncology, 2015, 13(4), 232‐234. • added to CENTRAL: 2015 2015 • Embase. Embase.",
      "text": "Reason for exclusion: Review article / trial. trial. 2: in in hepatocellular",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "2018, 2018, (no pagination) Added to CENTRAL: 2018 2018 • 6, 6,",
      "text": "for for exclusion: trial. trial. 3: Unresectable Unresectable Hepatocellular",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "Carcinoma: 1 1 - to to CENTRAL: 30",
      "text": "April 2018 • for for exclusion: trial. trial. 4: hepatocellular hepatocellular carcinoma: opinion opinion on",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "Pharmacovigilance, 2016, 17(14), 1923‐to to CENTRAL: 2016 2016 • 11, 11,",
      "text": "for for exclusion: trial. trial.",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "PRISMA",
      "text": "e e d",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "I",
      "text": "c c S",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "y",
      "text": "lc lc n",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "I",
      "text": "Applica A flow",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "PRICE",
      "text": "searching searching rches: epatocellula epatocellula (n = g g (__MEDTERM0_AND __MEDTERM0_AND noma; vima vima ma) duplicates duplicates (n=43) Records screene (n=143) l-text articles as",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "for religion",
      "text": "(n = 43) Studies included (n=1) d d (othe othe (n= F F e) exclu exclu (n=0) reason reason (n=22) n n e",
      "start_page": 106,
      "end_page": 107
    },
    {
      "heading": "I",
      "text": "c c S",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "y",
      "text": "lib ig ilE",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "d",
      "text": "a",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "d",
      "text": "u lc n",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "I",
      "text": "Applica",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "RISM",
      "text": "2009 2009 Reco",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "data bass",
      "text": "Flow Flow D",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "word identifi",
      "text": "see searching rches: epatocellula epatocellula (n = 0 0 Diagram",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "ied through",
      "text": "g (atinib_AND atinib_AND NOMA; Lenv ar carcinoma",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Records",
      "text": "Cochra Cochra h",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "with",
      "text": "vima ma)",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "s after duplicates",
      "text": "(n = 18)",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Records screen",
      "text": "(n = 18) l-text articlesasse",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "for religion",
      "text": "(n = 5)",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Studies included",
      "text": "(n = 1) ane",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Addi",
      "text": "th s remo",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "d",
      "text": "itiona itiona hroug",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "rary",
      "text": "othe othe (n =",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "word id",
      "text": "F F NTR",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "dentifie",
      "text": "RAL RAL sear",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "eccords exclu",
      "text": "(n = 13) reason reason (n=4) Pag rch",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "exclude",
      "text": "49 49 o",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "ded,",
      "text": "of 58",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "included included studies",
      "text": "107 107 (1) risk risk (L/L) years years (country country legislation) Baseline Baseline (gonadotropin gonadotropin [B-hCG] 25 25 IU/of of B-hAG). the the Commission'108 108 (3) 107 107 (1) the the subject'sorafenib sorafenib (the the recipients) virus virus (HIV) treatment treatment (hepatitis hepatitis virus) the the study",
      "start_page": 108,
      "end_page": 112
    },
    {
      "heading": "liver liver transplant",
      "text": "__MEDTERM0_ Group (n=478): 12 mg/bodyweight bodyweight ≥ 8 8 mg/ weight weight < dose_MEDTERM1__ dose_MEDTERM1__ (n=476): daily daily (BID) aetiology aetiology (_MEDERTM2_91 (19 %) 126 126 (26 %)) median median (IQR) (2 2 ng/mL). the the intention-the the 95% excellence. excellence. (Surveys) ==== @i=i=ii=i_i=u=i+i= i=i__i=n=i-i=g=i/i=j=i^i=w_i_a=i#i=:i=I=i%i=you=i[i=h=i]i=t=i*i=e=i&i=y=i.i=ow_i _i=o=defined defined as: (1, 1,902) Relation Relation Risk: RR: 970 970 (176/476)/(181/475)=0.970 • Treatment treatment- 4 4 (6.9-8.8) 7 7 (3.6-4.6) mon HR: 0.87 CI: 0.75",
      "start_page": 112,
      "end_page": 115
    },
    {
      "heading": "PICO PICO (clinical question)",
      "text": "from from DMC: the the following: DM DM C: the the following: 1.",
      "start_page": 116,
      "end_page": 117
    },
    {
      "heading": "Question 4 Response",
      "text": "the the Commission'107 107 (3) (c) Union Union (\"TFEU') 108 108 (3) TFEU. TFEU. (i.e., PR, PR, non-CR/investigators. investigators. ** value value > 125 days) weeks weeks + 2 weeks (criteria criteria (No. No. 7). Products Products for",
      "start_page": 117,
      "end_page": 119
    },
    {
      "heading": "carcinoma carcinoma (12/12/2018)",
      "text": "enclosed enclosed Eisai'carcinoma carcinoma (HCC). review review (SLR) folder folder (References/SLR References).",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "1. Summary: of of evidence",
      "text": "4 4 (1) (b) of Regulation (EU) No 575/Regulation. Regulation.",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "treated treated (3 in total) low low (2.5%) and balanced across",
      "text": "respect respect to",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "prognostic factors: alpha-fetoprotein alpha-fetoprotein (AFP) >200 ng/the the lenvatinib",
      "text": "survival survival (_MEDTERM2__) the the progression- free survival",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "3. 3.",
      "text": "manual manual (1) baseline, baseline, >98% analysis analysis plan",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "Overall Overall survival",
      "text": "assessment assessment report: trial. trial.",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "__MEDTERM0_group __MEDTERM0_group (13.6 months) than the __MED",
      "text": "Medi-fetofund Medi-fetofund (AFP) classification classification factors: Region: Region 1 (Asia-Pacific); Region 2 (America, America, elsewhere)",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "respectively; 856 856 [95% CI:0. 0.995], p=0.0342) (1).",
      "text": "follow-up. follow-up.",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "arm (43.1%) __MEDTERM0_ __MEDTERM0_ (SOR) arm (51.1%) which",
      "text": "survival survival (0 0 months) not not (9 9 months) for for post- 77 77 (95% 1. 1.0",
      "start_page": 121,
      "end_page": 122
    },
    {
      "heading": "overall overall survival",
      "text": "imbalance imbalance (3).",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "overall overall survival",
      "text": "2 2 \"survival survival analysis\" of the applicant's original",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "73. 73.4% 73. 73.5% of",
      "text": "was was 6% Excellence Excellence (NICE) Group Group (ERG) uncounted uncounted earnings",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "months months (4).",
      "text": "856 856 [95% CI: 0. 0.995], simultaneously simultaneously (the the publication).",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "events events (page effects)",
      "text": "events events (AEs) (effect effect estimates).",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "__MIDTERM1__. __MIDTERM1__. When",
      "text": "grade grade ≥ treatments. treatments.",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "in in ≥ 5% decreased, decreased,",
      "text": "increased increased and",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "in in ≥ 5% sorafenibarm sorafenibarm were",
      "text": "other other VEGF/VEGFR-targeted investigations; TEAEs TEAEs (>30% of patients) of of AE'action action . TEEAS TEEAS (> 30% of patients), earned. earned.",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "of of interest",
      "text": "hepatotoxicity hepatotoxicity (hepathic failure/ hepatic encephalitis) 47. 47.7% (227/476) __MEDTERMO_arm, __MEDTERMO_arm,",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "41. 41.7% (198/475) exposure, exposure, the",
      "text": "arms arms (1.96 events/the the __MEDTERM1_arm). Table 1: Overview of Hepatovevisey",
      "start_page": 123,
      "end_page": 124
    },
    {
      "heading": "least least 1: (N=476) (N=375) (N=496) ( N=1327)",
      "text": "SY=324.2 SY=239.1 SY=340.0 SY=1544.7",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "episodes episodes (episodes/SY) 635 (1.96) 481 (2.01) 659 (1.94) 619 (0.50)",
      "text": "n n (%) SAE,n (%) 71 (14.9) 34 (7.2) 73 (14.7) 19 (1.4) episodes episodes (episodes/SY) 97 (0.30) 40 (0.17) 100 (0.29) 25 (0.02)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "n n (%) 26 (5.5) 14 (2.9) 27 (5.4) 11 (0.8)",
      "text": "n n (%)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "35 35 (7.4) 20 (4.2) 36 (7.3) 25 (9.9)",
      "text": "58 58 (12.2) 45 (9.5) 58 (11.7) 50 (3.8)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "Monotherapy Safety Set: 2016 2016 (for ongoing studies). Set, Set, 85% of subjects received",
      "text": "future. future.",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "score score ≥ 6 (of of 7), greater liver",
      "text": "event event (study study [PSS] management management plan) safety safety (mainly creative-related events).",
      "start_page": 124,
      "end_page": 125
    },
    {
      "heading": "Progression-free Progression-free survival",
      "text": "methods methods (5) progression. progression.",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "sorafenibarm sorafenibarm [HR: 0.66; 95% CI: 0. 0.77; p<0.001]).",
      "text": "Table Table 2: events events • Set Set •_MEDTERM2_____MEDERTM3_N=478 N=n n (%) 424 (88.7) 431 (90.5) 329 329 (68.8) 374 (78.6) Death 95 (19.9) 57 (12.0) n n % 54 (11.3) 45 (9.5) 1 1 (0.2) 6 6 (1.3) 3 (0.6) data data (5.7) cut-off 43.7) 39 (8.7)",
      "start_page": 125,
      "end_page": 126
    },
    {
      "heading": "life life (HRQoL)",
      "text": "instrument instrument (EORTC QLQC30), module module (EorTC Q LQ-HCC18), visit. visit.",
      "start_page": 126,
      "end_page": 127
    },
    {
      "heading": "diarrhea, diarrhea, (EORTC QLQ-C30), image image (EorTC Q LQ-HC18) (9).",
      "text": "• QLQ-C30 domain (p-value p-value [log-rank test]):",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.83 (0. 0.97), p = 0.0098",
      "text": "• Pain: months, months, dependingly",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.82 (0. 0.95), p = 0.0060",
      "text": "Diarrhoea: months, months, respectively",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.53 (0. 0.63), p < 0.0001",
      "text": "• domain domain (p-value p-value [log-rank test]):",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.79 (0. 0.93), p = 0.0041",
      "text": "Nutrition: months, months, respectively;",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR: 0.81 (0. 0.95), p = 0.0060",
      "text": "groups groups (p > 0.05). __midterm1_ __midterm1_ . Figure 1: EOR EOR me-30 30 & mains mains (Vogel, 2017)",
      "start_page": 127,
      "end_page": 128
    },
    {
      "heading": "3.",
      "text": "ESMO ESMO guidelines: • in in first- function function (Child-Pugh A class), advanced advanced tumours",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "treatment treatment pathway",
      "text": "around around 50% therapy therapy (43.1% 51. 51.1% inthe __medTERM1__arm). undergo undergo post- treatment anti- survival survival (_MEDTERMM9___), time-to progression (TTP), rate rate (with with ___MEDT), objective response (__MEDM10_), and theHRM.",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "Unmet Unmet need",
      "text": "new new first- than than year; 4",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "(12) improve improve survival",
      "text": "as as possible; __midterm21__ __midterm21__ (of of HCC). assessment. assessment.",
      "start_page": 130,
      "end_page": 132
    },
    {
      "heading": "Electronic Electronic databases",
      "text": "Table Table 3: e-publications e-publications ahead-Cochrane Cochrane library; Oct Oct Abbreviations: Trials. Trials.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "2. 2. Hand-searching",
      "text": "years years (2016-2018):",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "# Liver Liver Neoplasms/ or Carcinoma, Hepatocellular/ 2 (Heptocellular carcinoma* or carcinoma* hepatocellular or hepatocarcinoma* cell cell carcinoma*hepatic hepatic cancer) 3 3 (((liver or hepato*) and (carcinom* or cancer*or neoplasm*or malignan*or tumo*) or HCC).ti, 4 or/1-3 5 (unresect*or or metastatic).7 7 (_MEDTERM0_or lenvima).ti;ses ses (AASLD) SPOR) Results oma* ab. ab. ,ab. 222 222",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 5: search search string",
      "text": "# Liver Liver Neoplasms/ or Carcinoma, Hepatocellular/ 2 (Heptocellular carcinoma* or carcinoma* hepatocellular or hepatoma* cell cell carcinoma*hepatic hepatic cancer) 3 3 ((liver or hepato*) and (carcinom* or cancer*or neoplasm*or malignan*or tumo*) or HCC).4 4 or/1-3 5 (unresect*or or metastatic).ti;5 5 (_MEDTERM0_or lenvima).ti.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Eligibility Eligibility criteria",
      "text": "107 107 (3) (c) 107 107 (1) TFEU. TFEU.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "included included studies",
      "text": "2. 2.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "included included studies",
      "text": "Table Table 7: Table Table 8: review review (n=3) Recognition Recognition (ASCO GI) document. document.",
      "start_page": 135,
      "end_page": 139
    },
    {
      "heading": "Table 1: first-line first-line treatment",
      "text": "response response (OR) [Jan Jan 18]. Available from:",
      "start_page": 139,
      "end_page": 140
    },
    {
      "heading": "treatment treatment sequenceing",
      "text": "path path • the the EPAR: •carcinoma carcinoma • list list •after after first- HCC HCC (1 1 below)",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "Figure 1: Updated NCCN guidelines",
      "text": "treatment treatment • rates rates (without without treatment), possible. possible. • patients, patients, (1) only 31% line line care",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "Figure 2: HCC treatment pathway",
      "text": "recommended recommended •tolated tolated __MEDAM2___^ 64. 64.8% 45. 45.4% 39. 39.2% status. status. (2) guidelines. guidelines. (3)(4) References:",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "Contents",
      "text": "S S , . . .. . . ...... 2 Background ................... C C RFA: RR: SAE: Q Q ESMO: GRADE: HCC: HR: ITT: MeSH: OR: ___MEDTERM1_DJO: PICO: RCA: RAC: CI: EMA: Q Q ESMO: GRADE: HC: HC: IATT: MESH: on on .................... ....",
      "start_page": 144,
      "end_page": 145
    },
    {
      "heading": "of of 13",
      "text": "ntion, ntion,",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "1 Purpose",
      "text": "of of ~indicated indicated (see Table 1). protocol. protocol.",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "2 Background",
      "text": "cancer cancer (hepatocellular carcinoma, HCC) year year (in in men; in in women) [1]. liver liver [2]. 37 37 % 40 40 % women women [1].",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "Current Current treatment",
      "text": "Cancer Cancer (BCLC) treatment treatment [3]. disease disease (BclC A) ablation ablation (or or hyper-/treatment treatment (RFA) in in Denmark) 50-75 50-75 % treatment treatment [3].",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "of of 13",
      "text": "stage stage (BCLC stage C), symptoms symptoms and/spread spread [3]. year year [4]. __MEDARM0_ __MEDARM0_ [5]. health health and/ Child Child -symptomatically symptomatically [3].",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "2.2 Lenvatinib",
      "text": "mg mg (weight weight < 60 kg) mg mg ( weight weight ≥ 60 kg), occur. occur. ~cancer. cancer.",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "3 Clinical issues",
      "text": "alternative alternative (s) targets. targets.",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "questions questions 1",
      "text": "to to __MIDTERM1__? and and B(7). 2. 2.",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "of of 13",
      "text": "occur. occur.",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "of of endpoints",
      "text": "risk risk (RR), odds ratio (OR) ratio ratio (HR). categories categories (adverse adverse events). Efficacy objective* differences differences (absolute values) survival survival (__MEDTERM0_) (number of months) points points - drug drug users",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "of of 13",
      "text": "difference. difference. *value value [8]. survival survival (overall survival, __MEDTERM0_) percent. percent.",
      "start_page": 148,
      "end_page": 149
    },
    {
      "heading": "patient. patient.",
      "text": "medicine. medicine.",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "of of 13",
      "text": "treatment. treatment.",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "here. here.",
      "text": "affect affect patients' EorTC EorTC QlQ- isolated isolated symptoms/scale scale [10]. difficulties difficulties [11].",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "of of 13",
      "text": "value value [12]. difference difference [13]. data data (map. map.",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "4 Literature search",
      "text": "MEDLINE MEDLINE (or or Ovid) and CENTRAL (via Cochrane Library). In addition, EMA'reports reports (EPAR) comparators comparators ((s).",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "Pharmaceutical Indication",
      "text": "The The applicant'exclusion exclusion criterion:",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "of of 13",
      "text": "from from EMA's EPAR • comparison. comparison.",
      "start_page": 151,
      "end_page": 152
    },
    {
      "heading": "5 Data processing/analysis",
      "text": "population population (e.g. intention-to-treat (ITT), per-protocol) using using Bucher's method) difference difference (SMD).",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "of of 13",
      "text": "included. included.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "6 Other considerations",
      "text": "__MIDTERM0__. __MIDTERM0__.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "References",
      "text": "database database [Internet]. [Sep Sep 15]. Available from: dep.iarc.fr/NORDCan/DK/Lancet. Lancet. 2018;391(10127):1301 •14. 3. (DLGCG) cancer cancer (HepatoCellular Carcinom, HCC).cancer cancer (2015) SST [Inter Net]. 2015 [15. 15.].Available from: EMA EMA - 2017. 2017.",
      "start_page": 154,
      "end_page": 155
    },
    {
      "heading": "Medical Medical Council",
      "text": "Ø Ø medicieradet@Thomsen Thomsen (project- Nielsen Nielsen (d d pe: etode etode ator) cancer cancer varlig) for for ehusekapopekt_MED_MED",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading <Document information>",
      "text": "Row 1: Document details • Row 2: number number •1. 1.0",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading <Medical Medical Board>",
      "text": "Row 1: product product • Row 2: Trade name • Lenvima Row 3: Generic name ~_MEDTERM0__Row 4: Company • Eisai Row 5: ATC code ~L01XE29 Row 6: Row Row 7: Administration/dose ~mg mg (weight weight < 60 kg) mg mg ( weight weight ≥ 60 kg), Row Row 8: carcinoma carcinoma (HCC) treatment. treatment.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading <Council Council Recommendation> (column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: Company Row 4: Row Row 5: Row Row 6: Administration/dose Row 7: EMA indication",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading <Secretariat working group>",
      "text": "Row 1: Row Row 4: Associate Associate Professor: Row Row 5: Medical Medical Officer:Row Row 6: Chief Chief Doctor: Row Row 7: d. d. • Row Row 8: Row Row 9: Kjær Kjær Overmedicologist: Clinical Associator: Row Row 10: Brink Brink Farmaceutic",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading <Secretariat working group>",
      "text": "Row 1: Ø Ø + 00 00 medicieraadet@Row Row 2: Secretariat'Thomsen Thomsen (methodology methodology manager) Thea Christensen (medical consultant) Nielsen Nielsen (trade committee coordinator) Nielsen Nielsen (team leader)",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading <Secretariat Working Group> (from previous page)",
      "text": "Row 1: Version: Date/Change Row 2: 1.0·10.04.2019•Council. Council.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "heading heading <Amgros· assessment>",
      "text": "Row 1: from from 10-04-2019 • Row 2: Company/Eisai (requirer) • Raw 3: Medical treatment •_MEDTERM0__ (Lenvima) ■ Row 4: Indication • stage stage (BCLC stage C) or or B",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "heading heading <Other considerations>",
      "text": "Row 1: Population:Customer'Clinical Clinical Value-Insights: Amgross-Row 2: Row Row 3: Row Row 4: additional cost; Row 5: and added value; Row 6: i__Sorafenib i__Sorafenib (Nexavar) of of evidence; Low 7: Row Row 8: Row Row 9: Non-Row 10: Previously treated; Row 11: Row Row 12: 0-1 0-1 and",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Other considerations>",
      "text": "Row 1: Row Row 2: Clinical added value",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Other considerations>",
      "text": "Row 1: Row Row 2: Added Value",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Other considerations>",
      "text": "Row 1: Row Row 2: evidence quality",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Other considerations> (column 1)",
      "text": "Row 1: Population...Customer'Row Row 2: __Sorafenib __Sorafenib (Nexavar) • value value • Row Row 3: Row Row 4: with with ~ Row 5: ^Row Row 6: Previously treated − Row 7: have have ▪ Row 8: and and • Row 9: function function ■ Row 10: A A and",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Other considerations> (column 2)",
      "text": "Row 1: in the \"Amgros\" Row 2: \"Row Row 3: \"Row Row 4: \"Other costs\" Row 5: \"and added value\" Row 6: \"Not reasonable\"",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Other considerations> (column 2)",
      "text": "Row 1: Row 2: i",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading <Other considerations> (column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading < Other considerations> (from previous page)",
      "text": "Row 1: • Row 2: Cost element •_MEDTERM0__ (Lenvima) •Sorafenib_ (Nexavar) ■ Incremental costs • Raw 3: •(DKK) ● Row 4: ▪ Row 5: medical expenses •XX • XXx •2.XX • 7: Hospital costs ~172.070 £169.826 •2.244 • Row 7: External charges •13.854 £14.100 • 247 • 8: Hospitals Row 9: per per patient",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading <Other considerations> (column column 1)",
      "text": "Row 1: • Row 2: Cost element •_MEDTERM0__ (Lenvima) •Sorafenib (Nexavar) ■Row Row 3: •(DKK) Row 4: ▪ Row 5: Medical costs •XX •XX • Row Row 6: Hospital expenses •DKK DKK •169,826 • Row 7: Outdoor charges •13,854 •14,100 •247 • Bow 8: Hospitals Row 9: per per patient",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading <Other considerations> (column column 2)",
      "text": "Row 1: • Row 2: rites • Raw 3: • Rot 4: • Roll 5: •",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "heading heading < Other considerations> (from previous page)",
      "text": "Row 1 - Row 2 - Row 3 - Row 4 - Row 5 - Row 6 - Row 7 - Row 12 - Row 13 - Row 14",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 1)",
      "text": "Row 1: • Row 2: ■ Row 3: ▪ Row 4: ~ Row 5: − Row 6: ● Row 7:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: A Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: N Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: NV Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: VA Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: AT Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: T Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 8)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: TIN Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 9)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: NIB Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 10)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: B Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 11)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: (L Row 7: Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 12)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: E Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <Other considerations> (column column 13)",
      "text": "Row 1 - Row 2 - Row 3 - Row 4 - Row 5:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: • Application • Bow 3: • Raw 4: Pharmaceutical company: • Eisai • Rot 5: Commercial name: ■ Lenvima • Row 6: Generic name:~_MEDTERM0___ • Rye 7: Indication:• carcinoma carcinoma • Low 8: ATC code:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: • Proceedings • Raw 3: • Rot 4: at at Amgros: • 14-11-2018 • Bow 5: Final report completed: ■ 27-03-2019 • Roll 6: final final application: ~ 133 days• Row 7: Working group: ● Winther Winther Johansen",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: • Prices • Raw 3: ■ Row 4: prices prices (SAIP).",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row 1: • Row 2: • Application Row 3: ■ Row 4: Pharmaceutical company: • Raw 5: Commercial name: ~ Row 6: Generic name: * Row 7: Indication: · Row 8: ATC code:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row Row 2: • Proceedings Row 3: ▪",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)> (column 1)",
      "text": "three, three,",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)> (column 2)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <5 LENVATINIB (LENVIMA)> (column 8)",
      "text": "three. three...",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading <7 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: • Population • Competitor • Raw 3: • Bow 4: • pathen pathen •_MEDTERM0__ (Nexavar) • Low 5: systemically. systemically.• Row 6: status status • function function • Row 7: and and B",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: Pickup Service • pack pack • Source Row 3: • Order (DKK) • Raw 4: ■ Row 5: Lenvitinib (Len-vima) − 4 mg • 30 pcs. (blister)",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)>",
      "text": "Row 1: Lenvitinib (Len-Row 2: vima)",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (from previous page)",
      "text": "Row 1: • Row 2: • MedTERM0__-spartene • PD-stamen • Row 3: ■ Row 4: • % of patients • month month • Frequency per må-",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "five. five.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: AFP",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: INR",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: • Biochemistry",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: • CT scan",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: Admission",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: Home care",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: • Row 2: • • MEDTERM0__- Row 3: • Raw 4: • % of patients •% of patients",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: • 100%",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: 50%",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: 46%",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 3)",
      "text": "Row 1: • Row 2: -stage • Raw 3: • Rot 4: • moon moon • Frequency per moun",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 3)",
      "text": "Row 1: • 0,5",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 3)",
      "text": "Row 1: 0,67",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 3)",
      "text": "Row 1: • 1",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 3)",
      "text": "Row 1: 0,16",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 4)",
      "text": "four, four, ed--",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 4)",
      "text": "Row 1:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: % Row Row 5:",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 6)",
      "text": "Row 1: • Row 2: PD-st... Row 3: ■ Row 4: r·",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 7)",
      "text": "Row 1: • Row 2: tadie· Row 3: ■ Row 4: Frequency per maj- • Raw 5: down",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 7)",
      "text": "Row 1: 0,5·",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 7)",
      "text": "Row 1:0°",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 7)",
      "text": "Row 1: 1°",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 7)",
      "text": "Row 1: 0,4°",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (from previous page)",
      "text": "Row+Proi! (Region + 16+Still Still Again), Row, Riveland-Gcin-Stil-Gin-Nake-Nage-Nami-N-Nice-Nine-Nin-Clinical manuals: Clinical Bio-chemical; AFP (Recion Zealand, 2018) Row 8: Living function;40,00 •Laboratorymedi-ncinc Laboratorymedi-ncinc guides: Clinical bio-chemistry; AGP (Rection Zealand, 2017)",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: • Row 2: ▪ Row 3: ● Row 4: Ambulatory",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: Liver funktio",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: Complete Blood",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: Endoscopy",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: wall wall MRI",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 1)",
      "text": "Row 1: Nurse",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row Row 5:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: on Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: dcell Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: but Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 2)",
      "text": "Row 1: e Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: and Row 5:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 3)",
      "text": "Row 1: etal Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 6)",
      "text": "five. five.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 7)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 9)",
      "text": "Row 1: Row 2: Kr. Row 3: Row 4: Row 5: Row Row 6:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 9)",
      "text": "Row 1: Row Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 9)",
      "text": "Row 1: Row 2: Row Row 3:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 9)",
      "text": "Row 1: Row Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 9)",
      "text": "Row 1: Row 2: Row Row 3:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 9)",
      "text": "Row 1: Row 2: Row Row 3:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 10)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: 0 Row 6:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 10)",
      "text": "Row 1:0 Row 2:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 10)",
      "text": "Row 1: Row 2: 0 Row 3:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <9 LENVATINIB (LENVIMA)> (column column 12)",
      "text": "Rowland, 2018-X+X (Region Zealand, 2018; 2016-Rowland; 2018; 2018-Nahland; 2017) •Ambulant DAGS tariffs: ce Row 5: CEBG50A+DG30L (Rage datasty-.Row 6: ^Labelmedi-cincincinc Labelmedi-cincincinc guides: Clinical Bio-chemical; AFP (2018, 2018, 2018) Row 8:",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "heading heading <12 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: \"Progression-free\" stage (PFS) • Progressed-stage (PD) ■ Row 3: \"Row 4: \"Hospital costs\" DKK DKK \"9,176,\"40 DKK \"Row 5: Municipal costs\" DKK DKK \"807,62\" Row 6: \"Total\" DKK DKK \"DKK DKK \"",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <12 LENVATINIB (LENVIMA)>",
      "text": "\"Rowhamattransfers', \"ROW', 'and and '4' patients, patients, 'patient patient ≥1 event^\" Row 3: \"Side areas' Row 4: 'Row 5: '__Lenvatinib___Sorafenib_",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <12 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row 1: • Row 2: • Progression-free-stad Row 3: • Raw 4: • Hospital costs • Row Row 5: Municipal costs ■ Row 6: • Total • kr. kr.",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <12 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row 1: • Row 2: • Grad 3- and 4% of patients • Rot 3: • Side effects • Raw 4: ▪ Row 5: •_MEDTERM0___ • Sorafeni Row 6: Elevated aspartatami- notransferase • 5,04 • Bow 7:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <12 LENVATINIB (LENVIMA)> (column 2)",
      "text": "Row 1: • Row 2: die (_MEDTERM0__) • Progressed stage (PD) ~ Row 3: ■ Row 4: ^40 40 £5: − 807,62 £6: • 02 02 £5.00",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <12 LENVATINIB (LENVIMA)> (column 2)",
      "text": "Row 1: # Row 2: # patient patient ≥1 event # Row 3: # Row 4: ib~Lenvatinib_____medterm1___ • Row 5:",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: Cost element ■_MEDTERM0__ (Lenvima) •_MEDTERM1___ (Nexavar) ~Incremental costs • Raw 3: •(DKK) ● Row 4: • Bow 5:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)>",
      "text": "Row 1: Sorafenib Row 2: (Nexavar)",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row 1: • Row 2: Cost items •_MEDTERM0__ (Lenvima) • _medterm0___ (Lendima) Row 3: • Raw 4: • Medical costs • Row Row 5: Hospital costs ■ Row 6: • at at • DKK DKK • Row 7: hospital 8: patient patient •",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)> (column 2)",
      "text": "Row 1: • Row 2: •_MEDTERM0__ (Nexavar) • Inkr Row 3: ■ Row 4: • Raw 5: •XX • Row 6: ~166.636 • Row 7: ^13.831 • Roll 8: ▪XXx •",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)> (column 3)",
      "text": "Row 1: Row 2: Row Row 3: (DKK) Row 4: Row 5: XX DKK",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)> (column 3)",
      "text": "Row 1: Row 2: - Row Row 3:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)> (column 4)",
      "text": "Row 1: Row 2: Cheese Row 3: Row 4: Row 5: K",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)> (column 4)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <14 LENVATINIB (LENVIMA)> (column 5)",
      "text": "Row 1: • Row 2: • Row 3: ■ Row 4: ▪ Row 5: ·",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "heading heading <15 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: ScenarioLenvatinib (Lenvima) •_MEDTERM1___ (Nexavar) ■Incremental costs (DKK) Row 3: ▪ Row 4: Processing Processing Include- ret_",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading <15 LENVATINIB (LENVIMA)>",
      "text": "Row 1: Sorafenib Row 2: (Nexavar)",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading <15 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: Cost element •_MEDTERM0__ (Lenvima) •Sorafenib_ (Nexavar) ■Row Row 3: •(DKK) Row 4: • Raw 5: Retail costs •XX •2.XXx •.XX € 6: Hospital expenses •DKK DKK •169,826 £2.244 • Row 7: External charges •13.854 £14.100 •247 £8: per per patient",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading <15 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row 1: ~ Row 2: Scenario__Lenvatinib (Lenvima) ~_MEDTERM1__ (Nexavar) SorafenibRow 3: • Nexavar) Row 4: ^ Row 5: Processing Processing Include- __MIDTERM3___---------------XX £*XXx • Row 6: Spill Include__MEDERTM3 ___",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading <15 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row 1: • Row 2: Cost item •_MEDTERM0__ (Lenvima) •Sorafenib [Nexavar] • • MEDTERM1__ (Nexavar) Row 3: ■ Row 4: Retail costs • XX DKK •Row Row 5: Hospital expenses • DKK DKK ● Row 6: hospital hospital • DKK DKK ~ 14,100 • Row 7: patient patient • XXx DKK",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading <15 LENVATINIB (LENVIMA)> (column 2)",
      "text": "Row 1: • Row 2: • Incremental costs (DKK) Row 3: • Rot 4: •XX • Row 5: ■XX DKK • Row 6: • XX DKK",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading <15 LENVATINIB (LENVIMA)> (column 2)",
      "text": "Row 1: • Row 2: • Incremental costs (DKK) •Row Row 3: •[DKK] Row 4: ■ Row 5: •Row Row 6:",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "heading heading <16 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: Analyzing •_MEDTERM0__ (Lenvima) •Sorafenib___Incremental costs • Raw 3: ~(DKK) ■ Row 4: ▪ Row 5:",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "heading heading <17 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: • processing processing • treatment treatment • Bow 3: • Raw 4: •Lenvatinib (Lenvima) •XX • • 0 DKK •",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "heading heading <18 LENVATINIB (LENVIMA)>",
      "text": "Row 1: • Row 2: • treatment treatment • Row Row 3: • Raw 4: • number number (8 patien- •XX DKK • Row Row 5: ● Row 6: number number (20 pati- enter) • XX •0 DKK",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading <18 LENVATINIB (LENVIMA)> (column 1)",
      "text": "Row 1: • Row 2: ▪ Row 3: ● Row 4: • number number (Row Row 5: ·ter)",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading <18 LENVATINIB (LENVIMA)> (column 2)",
      "text": "Row 1: • Row 2: • Recommended as • Row Row 3: ■ Row 4: en-",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading <18 LENVATINIB (LENVIMA)> (column 3)",
      "text": "Row 1: Row 2: Row Row 3: Row 4: Row 5: Row Row 6:",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading <18 LENVATINIB (LENVIMA)> (column 4)",
      "text": "two, two, ndling-- Row Row 4:--",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading <18 LENVATINIB (LENVIMA)> (column 5)",
      "text": "Row 1: Row 2: standard standard treatment",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading <18 LENVATINIB (LENVIMA)> (column 5)",
      "text": "Row 1: Row 2: 0 DKK",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "heading heading < 6 REFERENCER> (from previous page)",
      "text": "Row 1 - Row 2 - Regionernes • AMGROS I/S·TLF: 3 3 - SUBSEQUENT ORGANIZATION • DAMPWAY 27-29 • Row Row 4:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading < 6 REFERENCER> (column column 1)",
      "text": "Row 1: • Row 2: • • Region Row 3: • \"M Row 4: •",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading < 6 REFERENCER> (column column 2)",
      "text": "Row 1: Row 2: NERN Row 3: MIDD Row 4:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading < 6 REFERENCER> (column column 3)",
      "text": "Row 1: Row 2: NES Row 3: DELOR Row 4:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <6 REFERENCER> (column column 4)",
      "text": "Row 1: Row 2: Row 3: RGAN Row 4:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <6 REFERENCER> (column column 5)",
      "text": "Row 1: Row 2: Row 3: NISSAT Row 4:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <6 REFERENCER> (column column 6)",
      "text": "Row 1: Row 2: Row 3: TION Row 4:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <6 REFERENCER> (column column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <6 REFERENCER> (column column 9)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <6 REFERENCER> (column column 10)",
      "text": "Row 1: • Row 2: • AMGROS I/S Row 3: •Row Row 4: • Row Row 5: •",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading < 6 REFERENCER> (column column 11)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5:",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading < 6 REFERENCER> (column column 12)",
      "text": "Row 1: ▪ Row 2: TLF: Row Row 3: • Row Row 4: ·",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "heading heading <assessment assessment (of of report)>",
      "text": "Row 1: Trade name: •Lenvima Row 2: Generic name •_MEDTERM0_Row 3: Company •Eisai Row 4: ATC code • L01XE29 Row 5: Row Row 6: Administration/dose •mg mg (weight weight < 60 kg) mg mg ( weight weight ≥ 60 kg), Row Row 7: carcinoma carcinoma (HCC) Row Row 8: March March 2019",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <assessment assessment (of of report)> (column column 3)",
      "text": "Row 1: Lenvima Row 2: __MEDTERM0_Row 3: Eisai Row 4: L01XE29 Row 5: Row Row 6: mg mg (weight weight < 60 kg) mg mg ( weight weight ≥ 60 kg), Row Row 7: •carcinoma carcinoma (HCC) Row Row 8: 1. 1.0",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: Row Row 2: Overall survival: Safety Safety (side effects) Pharmacokinetics",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "%===+==&gt;== &gt; ==&lt;= &lt; = ## &gt: ### &amp; ##[&lt:== ##&gt: €1; $; #; &lt: #; #2; #; _BAR_= #;; #!; # #; [page] 5; performance performance status·0: 64 %; $; $3; $;; $6; #; =;;; -;; _ _ _",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <of of 21> (column 1)",
      "text": "Row 1: Row Row 2: Overall survival",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <of of 21> (column 1)",
      "text": "Row 1: Row 2: Age (median, interval) Row 3: % Women Row 4: Row Row 5: Row Row 6: Row Row 7: Row Row 8: Row Row 9: Aetiology- Row Row 10: Cancer Cancer stage",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "Row 1: Sorafenib (n = 476) Row 2: 62 (22-88) Row 3: 16% Row 4: 0: 63 % 1: 37 % Row 5: A: 99 % B: 1% Row 6: Yes: 19 % No: 81 % Row 7: Yeah: 62 % No; 38 % Row 8: yes: 76 % NO: 24 % Row 9: Hepatitis B: 48 % Hepatitis C: 26 % Alcohol: 4 % Other: 7 % Unknown: 14 % Row 10: B (intermediate): 19 % C (advanced): 81 %",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • assessment assessment •Results Row 2: Absolute differences •Media survival: months months survival: 8 % month month survival: 4 % points • Median survival: month month survival",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • assessment assessment •Results Row 2: Absolute differences •5 %-point •2 %-points [-2;5] Row 3: Relative differences ■added added • limit limit < 0.75 • Row 4: •Important value added• limit limit < 0,90 • Raw 5: • Small added value• limit limit < 1,00 • Bow 6: ● value value • limit limit > 1,00'RR: 1,23 [0,79;1,90] Row 7:",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • assessment assessment •Results Row 2: Absolute differences •10 %-points •-1 %-point [-7; 5] Row 3: Relative differences ■added added • credit credit < 0.75 • Row 4: •Important value added• charge charge < 0.90 • Low value • charge charge ≤ 1.00 • Raw 6: •value value ~ Upper limit > 1.00•RR: 0.97 [0.82; 1.14] Row 7:",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • assessment assessment •Results Row 2: Absolute differences •10 % 18 18 events/patient-year •-0.20 [-0.42; 0,01] events/ patient-year Row 3: Relative differences ●value value • threshold threshold < 0.75 • Row 4: •Important added value• limit limit < 0.90 • Raw 5:",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • for for assessment•Results Row 2: Absolute differences•Median progression-free survival: 3 months•Row Row 3: Relative differences•Large value added•Overcouple threshold < 0.75• Row 4: •Important added value•Opercouples limit < 0.90•HR: 0.66 [0.57;0.77] Row 5: •added added • limit limit < 0.10• Row 6: ●value value •limit limit > 1.00• Row 7:",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: Targets of effectiveness:Quality: Value Row 2: Overall Survival:Critical:No Row 3: Side effects:Criteric: No Row 4: Progression-free survival • Important Row 5: life life • Non-documentable Row 6: added added value",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "heading heading <Secretariat working group>",
      "text": "Row 1: Row Row 2: of of Medicine: Row Row 3: Members • Row Row 4: Officer Officer • Row Row 5: officer officer • Row Row 6: Row Row 7: PhD PhD • Row Row 8: appointed appointed •Row Row 9: Professor Professor • Row Row 10: Brink Brink Farmaceuticuut",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "heading heading <Secretariat working group>",
      "text": "Row 1: Ø Ø + 00 00 medicieraadet@Row Row 2: Secretariat'Thomsen Thomsen (methodology methodology manager) Thea Christensen (medical consultant) Nielsen Nielsen (trade committee coordinator) Nielsen Nielsen (team leader)",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "\"Rowway 1: account. account.'to to risk:estimated. estimated.'Surdering •Beground Row 2: generation generation (selection bias) • for for bias/randomised randomised 1:region region (Asia-Pacific/West), invasion invasion (yes/no), extrahepable spread (yes /no), superchematic spread (y/n), spread spread (J/N), performance statur (0/1) and weight (</≥ 60 kg). Row Row 20: the the patient'Row Row 21: with. with. • Row 22: Progression-free survival • Row Row 23: blind blind ▪ Row 24: Row Row 25: target. target.",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: Row Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • Row Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • Row Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: Row Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "Row 1: • Row Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 1)",
      "text": "Row 1: Risk of bias",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 1)",
      "text": "Row 1: Allocation concealmen (selection bias)",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: Low Low 5: Progression-free survival",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 1)",
      "text": "Row 1: Selective reporting (reporting bias)",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "Row 1: assessment",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "Row 1: nt Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "Row 1: • bias bias • Row Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "Row 1: ssessment (detection bias) ... Row 2: • Row Row 3: • Row 4: • disability disability • Row Row 5: ■ Row 6: ● bias bias •Row Row 7: ▪ Row 8: • baas baas • low risk ofbias",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "Row 1: Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "Row 1: • of of bias• Row Row 2:",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 3)",
      "text": "Row 1: • Reason • Row 2: • randomized randomized 1:region region (Asia-Pacific/Western), invasion invasion (yes/no), extraHepathic spread (yes / no), spread spread (Yes/no); performance stature (0/1) and weight (</≥ 60 kg).• Row 3: • independent independent • Bow 4: • with with • Raw 5: interactive interactive • Row 6: System. System.",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21> (column 3)",
      "text": "the the patient'with. with. • Row 3: with with .",
      "start_page": 56,
      "end_page": 56
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "5 mnot: 12 m: 12 to 12: 12 nown-/square square stone-wood-stone-/-patientsEffect. patientsEffect.Certainty*Importance",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "heading heading <of of 21> (column 1)",
      "text": "Row 1: • Row 2: •Certainty assessment • Row 3: ■ Row 4: • Ruw 5: • No of • Studied design • Inconsistency Inconsistency • Indirect Row 6:",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "heading heading <of of 21> (column 2)",
      "text": "2 2 ,3 3 ,9 9 ,11 11 ,12 12 ,17 17 ,15 15 ,09 09 ,26 26 ,19 19 ,18 ,23 ,.",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "heading heading <of of 21>",
      "text": "\"Rows' Row Row 2: \"Certainty assessment', \"No of patients'Effect 'Certity'Importance' Row 3: 'Row 4: 'No of",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "heading heading <Contents> (from previous page)",
      "text": "Row 1: Phone Phone +market. market.access@Row Row 2: Phone Phone +market. market.Access@dra",
      "start_page": 60,
      "end_page": 60
    },
    {
      "heading": "heading heading <kinase kinase inhibitors>",
      "text": "market, market, Row: Generic nameLenvatinibRow 3: in in Denmark; \"Row Row 4: Row Row 5: Pharmacotherapeotic group 'Row Row 6: Active substances (s) ]_MEDTERM0_ROW 7: Pharmaceutical forms) Row 13: Combination therapy and/Row Row 14: Packaging types, sizes/capsules. capsules.Polyamide/Aluminium/PVC/Row Row 15: Orphan drug designing",
      "start_page": 61,
      "end_page": 61
    },
    {
      "heading": "heading heading <kinase kinase inhibitors> (from previous page)",
      "text": "right right OhRow-down-fetoprotein Row 4: Row Row 5: ALT/Row Row 6: Row Row 7: Row Row 8: BCLC^Row Row 9: BID=Row Row 10: BP !Row Row 11: Row Row 12: Row Row 13: 0 0 13: Row Row 14: CTwew 10: CT",
      "start_page": 62,
      "end_page": 62
    },
    {
      "heading": "heading heading <included included studies>",
      "text": "Row 1: Reference (journal, journal, year)",
      "start_page": 65,
      "end_page": 65
    },
    {
      "heading": "heading heading <by by subgroup>",
      "text": "Row 1: •_MEDTERM0_Sorafenib_ • Row 2: •(N=478) • • Row 3: • n (%) • row 4: Deaths, n (%) 73.4) •350 (73.5) • town 5: n n (%) Alive Alive •127 (26.6) 5 (1.0) 13 (2.7) 109 (22.8) ^126 (2.5) 11 (2.3) 8 (2.7) 107 (22.5) • bow 6: Survival Survival (months)a (95% CI) 13.6 (14. 14.9) • 12.3 (13. 13.9) Row 7: Rate Rate (%) (95% CI), Months Months +80.8 (84. 84.1) 55.0 (59. 59.4)",
      "start_page": 70,
      "end_page": 70
    },
    {
      "heading": "heading heading <Overall Overall Survival>",
      "text": "Sex (Male, Female, Female) Region (Asia-Pacific, Western Region) Invasion Invasion (Yes, No) Extrahepetic Spread (yes, No), Invassion Invassion (Is, No); Extrahepathic Spread (Yes; No) Macrocopic Portale) Both Both (Yes/No) __MEDTERMM2__ (0, ≥1) Body Weight (<60 kg, ≥ 60 kg) Baseline Baseline (<200 ng/mL, ≥ 1,200 nn/m L, ≥ 200 ng /mL) C C (Yes, thereto, No).",
      "start_page": 72,
      "end_page": 72
    },
    {
      "heading": "heading heading <survival survival analysis>",
      "text": "Row 1: •_MEDTERM0_Sorafenib_ • Row 2: •Western (N=157) •western •Asia-Pacific (N=326) ■Total • Rotal (N=478) •Total ~Western (N-157) •Western •Asia-Pascific [N=319) ^Total (N=476) − Total • Round 3: • • N=157] • Joint • Western • Eastern • Asia-Parcific • Northern • Southern • Upper • Top • Average • Low • Lower • 162 (50.5) •206 (43.1) •71 (45.2) •172 (53.9) •243 (51.1) Row 5: medication medication (a a procedure) n n (%) •5",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "heading heading <survival survival analysis>",
      "text": "Row 1: Asia-Pacific Row 2: (N=321)",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "heading heading <survival survival analysis>",
      "text": "Row 1: Asia-Pacific Row 2: (N=319)",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "heading heading <survival survival analysis>",
      "text": "Row 1: \"Ratio Ratio (95% CI)*• Row 2: \"Without adjustment\": \"With adjustment†\" Row 3: Overall0.92 (1. 1.06) \"0.87 (1. 1.01) \"Row 4: Region Asia-Pacific Western\"\"0.86 (1. 1.02) \" 1.08 (1. 1.42) \"0.83 (1. 1.00) 0.93 (070, 1.23) \"",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "heading heading <survival survival analysis>",
      "text": "Row 1: \"with with baseline' Row 4: \"alpha-fetoprotein (AFP) levels ≥200 ng/mL (in in HCC), Row Row 5: 'the the __MEDTERM1_arm: 46% vs 39%, of of subjects",
      "start_page": 74,
      "end_page": 74
    },
    {
      "heading": "heading heading <adverse adverse events>",
      "text": "virus virus (HCV) recently recently ^26% vs 19%, relevantly), on on market-and and mail-Row Row 20: \"models. models.'Row 21: \"Row 22: 'Excellence Excellence (NICE) __MEDM10__ __MEDM10__ (ID089) [9]. [9].'. Row 23: \"Row Row 24: \"Row Row 26:",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "heading heading <adverse adverse events>",
      "text": "Row 1: Advertisement events__Lenvatinib (N=476) n (%)~Sorafenib_____ Row 2: •(N=475) • Row 3: ■n (%) • Raw 4: any any TEAAE^470 (98.7) •472 (99.4) • Bow 5: related related TEAE^447 (93.9) • 452 (95.2) • Row 6: TEAE TEAE ≥ degree •357 (75.0) • 316 (66.5) • Now 7: TEAe TEAe ≥ grade 3°270 (56.7)",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "heading heading <adverse adverse events>",
      "text": "Row 1: Lenvatinib Row 2: (N=476) Row 3: n (%)",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "heading heading <Median progression-free survival>",
      "text": "Row 1: Adversal events__Lenvatinib_____MIDTERM1___^Row 2: •(N=476) • (N=475) • Row 3: •Total duration= n n (AE rate) ■Total duration = n n [AE rate] • Raw 4: TEAE TEAE ≥TEAE TEAE ≥ events events † incidents incidents •6,124 (18.89) 3,546 (10.94) 1,023 (3.16) 517 (1.59) 409 (1.26) 61 (0.19) 379 (1.17) •4,718 (19.73) 2,865 (11.98) 795 (3.33) 430 (139) 232.90)",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "table under heading<hepatocellular hepatocellular carcinoma>",
      "text": "Row 1: Inclusion criteriaPopulation: OR OR Comparator: LenvatinibOutcomes: Overall survival (__MEDTERM2_) Events Events (AE) survival survival (__MEDTERM3_) Study Study design: Row Row 2: Exclusive criteriaPOPulation: Or Or Comparor: No __MEDERM0___Ounces: Study Study designs: 1 1 trial",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "heading heading <included included studies>",
      "text": "Row Row 4: node node (LN) measures measures greater",
      "start_page": 108,
      "end_page": 108
    },
    {
      "heading": "heading heading <included included studies> (from previous page)",
      "text": "B B (chemoemeemembeization chemoemeemembeization [TACE]) Cancer Cancer (BCLC) defined defined as: count count (ANC) X X 10^9/Hemoglobin Hemoglobin (Hb) years years (country country legislation) Baseline Baseline (gonadotropin gonadotropin [B-hCG] 25 25 IU/of of B-hPG). postmenopausal postmenopausal (other other knowledge;",
      "start_page": 109,
      "end_page": 109
    },
    {
      "heading": "heading heading <included included studies> (from previous page)",
      "text": "because because (before before ending), prevention prevention (e.g., method method [with with spermicide], satisfied satisfied azosomermia) for for advanced/unresectable HCC. Note: therapy therapy (transarential transarential [chemo] or or radiotherapy) treatment treatment (eg, eg, granulocytes",
      "start_page": 110,
      "end_page": 110
    },
    {
      "heading": "heading heading <included included studies> (from previous page)",
      "text": "1 1 above: \"0 0 (CTCAE v4.0). perpetuscular perpetuscular impact: Association Association (NYHA) __MIDTERM2__ __MIDTERM2__ (the the recipients) virus virus (HIV) treatment treatment (hepatitis hepatitis virus) the the study",
      "start_page": 111,
      "end_page": 111
    },
    {
      "heading": "heading heading <liver liver transplant>",
      "text": "Row 1: ^Row Row 2: InterventionLenvatinib (n=478): 12 mg/bodyweight bodyweight ≥ 8 8 mg/ bodyweight bodyweight < Sorafenib Sorafenib (n=476): daily daily (BID) Row Row 3: aetiology aetiology (_MEDERTM2_91 (19 %) and __MEDTERM3_126 (26 %))) median median (IQR) (2 2 ng/mL). %===%==$==#== ####=##+##_##%##[##&##*##;##__##•## (##]##!##,##^##\\##\"## >## [##)## the the 95% of of 0·of of 1·08.",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading <liver liver transplant> (column 5)",
      "text": "Row 1: Row Row 2: Lenvatinib (n=478): 12 mg/bodyweight bodyweight ≥ 8 8 mg/ weight weight < Sorafenib Sorafenib (n=476): daily daily (BID) Row Row 3: aetiology aetiology (__MEDTERM2_91 (19 %) and __MIDTERM3_26 %)) median median (IQR) (2 2 ng/mL). %===%==$==#==+==*== ####=##_##&##[##]##;##__##%## (##)##!##,##^##\\##•##.##S##~##\"## >## [##}## & ## ♪## _## $##£## the the 95% of of 0·of of 1·08.",
      "start_page": 112,
      "end_page": 112
    },
    {
      "heading": "heading heading <liver liver transplant> (from previous page)",
      "text": "the the Cochran-Mantel-Haam-Haven-at at α=0·05 (two-sided). progression progression - and and 95% Coch Coch ran-Man-Manel-CI. CI.",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading <liver liver transplant> (column column 6)",
      "text": "at at α=0·05 (two-sided).",
      "start_page": 113,
      "end_page": 113
    },
    {
      "heading": "heading heading <liver liver transplant> (from previous page)",
      "text": "according according to: N Result (CI) 0.ShHHiHHH2Row-way-space-way_right-way= right-wayway-way way (CI), \"Difference (Lenva-Sora) 'in in effect*Row Row 2: 13.6 (12.1/1-14.9) __MEDTERM0_478 months CI: (-3. 3.4) monthsHR: 0.92 CI: Diff Diff (Lenva-sorae) Row Row 3: _Lenvatinib476 month CI: (59. 59.4) % 0 0 (54. 54.5) (5) 5%",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "heading heading <liver liver transplant> (column column 3)",
      "text": "Row 1: Comments Comments •Row Row 2: HR: 0.92 CI: 06 06 •Diff (Lenva-Sora) •Row Row 3: HR: 0,92 CI; 0.79-106 •HR and 95% factor factor •Row Row 4: HR: 06 06 •running running • Raw Raw 5: Rate Ratio: 0.89 CI: (1. 1.01) •Distribution. Distribution.",
      "start_page": 114,
      "end_page": 114
    },
    {
      "heading": "heading heading <liver liver transplant> (from previous page)",
      "text": "Row 1: 4 4 (6.9-8.8) 7 7 (3.6-4.6) months CI: (4. 4.8) monthsHR: 0.66 CI: 0.57",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <liver liver transplant> (column column 6)",
      "text": "Row 1: Row Row 2: Figure 5.5",
      "start_page": 115,
      "end_page": 115
    },
    {
      "heading": "heading heading <carcinoma carcinoma (12/12/2018)>",
      "text": "Row 1: Row Row 2: carcinoma carcinoma (12/12/2018)",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "heading heading <arm (43.1%) __MEDTERM0_ __MEDTERM0_ (SOR) arm (51.1%) which>",
      "text": "Row 1: assessment assessment report:.. Row 2: •when when • Row 3: •trial. trial. • survival survival (OS) higher higher • Raw 4: •__MIDTERM2__group __MIDTERM2__group (13.6 months) __MEDERTM1_group __MEDERTM1_group (months months [hazard ratio (HR) 0.92, 95%",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "heading heading <score score ≥ 6 (of of 7), greater liver>",
      "text": "same same (as (%)227 (47.7), (157, (557, stock) Seawaywaywayways 1 (\"right-betweenNon-HCERow betweenNon-HCERow 4: _________=MEDTERM0_______Safety SetupRow5___^Ro Ro 5: •12 12 mg",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "heading heading <life life (HRQoL)>",
      "text": "7 7 (6, 6CI) Q1 (95%), Q3 (95% CI) 7Row 7Row (1,0), (9. 9.7) 32 (88.7) 95 (19.9),431 (90.5) 374 (78.6) 57 (12.0), Row 4: n n (%) No No post-No No progression: 54 54 (11.3)) 1 (0.3) 6 (0.3) 43 (9.0) 4 (0.88) data data run-the the turn-data data out-of-o.4) 3 (9.5) 0 3 (0.6) 39 (8.6) 39 (8.2) 3 (8, 6 (6.6) 3 (8.6) 39 (8, 3.6) 39 3 (3.6, 36) 39) 39, 36 (8, 3 (8) 38), 3 (S 3 (3 3 (8.) 41 3 (3 3 (ou), (8, 8), 13, 6: (including Rway)",
      "start_page": 126,
      "end_page": 126
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (from previous page)",
      "text": "Row 1: Figure 1: Time-QLQ-C30 QLQ-C30 & domain domain (Vogel, 2017) Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 1)",
      "text": "Row 1: Figure 1: Row Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 2)",
      "text": "Row 1: me-Row Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 3)",
      "text": "Row 1:Row Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 4)",
      "text": "Row 1: 30 30 & EO Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 5)",
      "text": "Row 1: Row Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 6)",
      "text": "Row 1: Row Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 7)",
      "text": "Row 1:Row Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "heading heading <HR: 0.81 (0. 0.95), p = 0.0060> (column column 8)",
      "text": "Row 1: mains mains (Vogel, 2017) Row 2:",
      "start_page": 128,
      "end_page": 128
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: In-Process. In-Process.Ovid·prior prior to",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: • 1 • Liver Neoplasms/ or Carcinoma, Hepatocellular/ • 141015 •",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: • 3 • ((liver or hepato*) and (carcinom* or cancer* or neoplasm* or malignant* or tumo*) or HCC). ti,ab.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: • 5 • • unresect* or or metastatic).ti.,ab. • 564744 •",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: •7 •(_MEDTERM0__or lenvima).ti,ab.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: Ovid Ovid • Row Row 2: .and e-publications ahead-of-print •search",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: • 1 • Liver Neoplasms/ or Carcinoma, Hepatocellular/",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: •3·((liver or hepato*) and (carcinoma* or cancer* or neoplasm* or malignant* or tumo*) or HCC).ti,",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: ...5·(unresect* or or metastatic).ti,ab.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: •7 •(lenvatinibor lenvima).ti.ab.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: or to • 11th December • Row 2: • 2018 •",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: \"141015\"",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: ,ab.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: \"564744'",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "Row 1: \"315'",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 1 • Liver Neoplasms/ or Carcinoma, Hepatocellular/ • 2535 •",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 3 • ((liver or hepato*) and (carcinom* or cancer* or neoplasm* or malignant* or tumo*) or HCC). ti,ab.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 5 • unresect* or or metastatic).ti,ab.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: •7 •(_MEDTERM0__or lenvima).ti,ab.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: adult adult (aged ≥ 18 years) unresectable, unresectable, or/and° Row 2: metastatic hepatocellular carcinoma",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: survival survival (OS) • Row 2: • survival survival (PFS) ■ Row 3: • Tumor response rate: complete response (CR), partial response (PR), overall • Raw 4: • Response rate (__MIDTERM2__) Row 5: • response response • Bow 6:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: •Linguistics •English language •",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: \"Countries': \"Unlimited'",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 1 • Liver Neoplasms/ or Carcinoma, Hepatocellular/",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 3 • ((liver or hepato*) and (carcinoma* or cancer* or neoplasm* or malignant* or tumo*) or HCC). ti,ab.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: ...5·(unresect* or or metastatic).ti,ab.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: •7 •(lenvatinibor lenvima).ti.ab.",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: adult adult (aged ≥ 18 years) Row Row 2: metastatic hepatocellular carcinoma",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: survival survival (OS) Row 2: • survival survival (PFS) Row 3: • Tumor response rate: complete response (CR), Row Row 4: • Response rate (__MIDTERM2__)",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: \"Language\"",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: \"Countries' Unlimited",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 253",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 832",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: • 531",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: •132",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: Row Row 2:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: Row 2: Row 3: nse (PR), ov Row 4: Row 5: Row 6: >=5% Row Row 7:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: 35°",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: 26°",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: 184·",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: 2·",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: r/and",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1: \" Row 2: \" Row 3: \" Row 4: \" Row 5: \" Row 6: \" Ents \" Row 7: \"",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "Table 5: search search string",
      "text": "Row 1:",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "heading heading <included included studies>",
      "text": "Row 1: 1· unresectable unresectable • Row 2: virus virus (HBV). Hepatology. 2017;Conference: 68th",
      "start_page": 135,
      "end_page": 135
    },
    {
      "heading": "heading heading <included included studies>",
      "text": "Row 1: 3· in in hepatocellular",
      "start_page": 135,
      "end_page": 135
    },
    {
      "heading": "heading heading <included included studies>",
      "text": "Row 1: 5·hepatocellular hepatocellular carcinoma° Row 2: health. health. 2017;Conference: annual annual european",
      "start_page": 135,
      "end_page": 135
    },
    {
      "heading": "heading heading <included included studies>",
      "text": "Row 1: 7· life life (HRQOL) and",
      "start_page": 135,
      "end_page": 135
    },
    {
      "heading": "heading heading <included included studies> (from previous page)",
      "text": "Row 1: 1·Row Row 2:",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <included included studies> (from previous page)",
      "text": "Row 1: Row Row 2: Kudo 2018",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "heading heading <included included studies> (from previous page)",
      "text": "Row 1: 3· study study of",
      "start_page": 136,
      "end_page": 136
    },
    {
      "heading": "Table 1: first-line first-line treatment",
      "text": "Row 1: line line treatment;anticancer anticancer medication;cancer cancer medication;",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "Table 1: first-line first-line treatment",
      "text": "Row 1: Row Row 2: treatment",
      "start_page": 139,
      "end_page": 139
    },
    {
      "heading": "heading heading <Figure 2: HCC treatment pathway> (from previous page)",
      "text": "limited. limited.",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "heading heading <Figure 2: HCC treatment pathway> (from previous page)",
      "text": "Row 1: Trade name: •Lenvima Row 2: Generic name •_MEDTERM0__Row 3: Company •Eisai Row 4: ATC code • L01XE29 Row 5: VEGF VEGF 1·3, FGF 1^Row Row 6: Administration/dose •mg mg (weight weight < 60 kg) mg mg ( weight weight ≥ 60 kg), Row Row 7: EMA indication •carcinoma carcinoma (HCC) reactions. reactions.",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <Figure 2: HCC treatment pathway> (column column 5)",
      "text": "Row 1: Lenvima Row 2: __MEDTERM0_Row 3: Eisai Row 4: L01XE29 Row 5: VEGF VEGF 1",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "heading heading <of of 13>",
      "text": "Row 1: Measure of efficacy*•Importability·City·Measuring unit•differences differences (absolute values) Row 2: survival survival (__MEDTERM0_) *Critical •Deathlessness •Median survival (number of months) •Row Row 3: •survival survival - months months •Row Row 4: •survival survival - months months ■Raw Raw 5: Side effects •Critically • reactions reactions •events events •Rotate Rotate 6: patient-years patient-years •Row Row 7: •adverse adverse events",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <of of 13> (column 1)",
      "text": "Row 1: Goals of action*•Importability·Categori°Row Row 2: Survival Survival (OS) *Critical ▪Deathlessness > Median Survival (months) Row 3: •Survival Survival - Row Row 4: •Survivors Survivors - Raw Raw 5: Adverse Reactions ---effects effects •Row Row 6: •Row Row 7: ●Row Row 8: ■Row Row 9: Progression-free survival (___MEDTERM1_) ]",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "heading heading <of of 13>",
      "text": "Row 1: life life • Important • of of life•difference. difference.•0,5 SD",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "heading heading <of of 13>",
      "text": "Row 1: Pharmaceutical • Indication Row 2: Lenvatinib___Hepatocellular carcinoma",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <of of 13> (column 1)",
      "text": "Row 1: Drug Row 2: Lenvatinib",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "heading heading <Medicin Medicin Council>",
      "text": "Row 1: Vice-Chairman: Row 2: Row Row 3: Members: Row Row 4: D. D., Row Row 5: Row Row 6: Row Row 7: Row Row 8: Hasn'Row Row 9: Associate Associate Professor",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "heading heading <Medicin Medicin Council>",
      "text": "Row 1: Ø Ø + 00 00 medicieraadet@Row Row 2: The Secretariat's Working Group: Gedske Thomsen (Method Method Manager) Nielsen Nielsen (Coordinator) Anker Anker Nielsen",
      "start_page": 155,
      "end_page": 155
    }
  ]
}